Market Assessment of Respiratory Diagnostics in the United States and Europe
Diagnosis of Lung Cancer and COPD is Driving the Market
NEW YORK, June 29, 2015 /PRNewswire/ -- This research service provides an analysis of the respiratory imaging diagnostics market in the United States and Europe. The service provides detailed analysis of the current and forecasted number of procedures, market size, and revenue forecast in respiratory diagnostics such as computed tomography, magnetic resonance imaging, positron emission tomography, x-ray, and spirometry. Market participants and key opinion leaders in the United States and Europe were interviewed to obtain perceptions of trends and opportunities in the respiratory diagnostics market. The study period is from 2011 to 2018, with 2013 as the base year.This research service provides an analysis of the respiratory imaging diagnostics market in the United States and Europe. The service provides detailed analysis of the current and forecasted number of procedures, market size, and revenue forecast in respiratory diagnostics such as computed tomography, magnetic resonance imaging, positron emission tomography, x-ray, and spirometry.
Market participants and key opinion leaders in the United States and Europe were interviewed to obtain perceptions of trends and opportunities in the respiratory diagnostics market. The study period is from 2011 to 2018, with 2013 as the base year.
Executive Summary
-New technology and applications continue to counter downward economic pressures.
-Computed tomography (CT): Lung disease imaging contributes to to % of the total CT scan procedures.
oA CT scan is recommended for smokers over the age of (approximately million of the total million smokers), and million CT scans have been performed on people under the age of in the United States.
oThe United States is the dominant region, with million lung-specific CT scans carried out every year; however, radiation exposure is a significant drawback of CT.
-Magnetic resonance imaging (MRI): Across geographies, the role of MRI for lung disease imaging is limited. Longer procedural time and a lack of precision to image a moving organ such as the lungs hamper the use of this type of imaging.
-Positron emission tomography (PET): This procedure is considered an alternative option for staging lung cancer, and it reduces radiation exposure when compared to CT. However, the high cost of equipment and the average cost of each scan is significantly high, which limits adoption in European countries as healthcare services are heavily subsidized.
-Healthcare service providers embrace radiation dose reduction technologies, reconstruction software, limited scan time, precise imaging of moving organs, and cost-effective products.
-The increasing incidences of lung disease across geographies provide a potential opportunity for technologies that satisfy the unmet needs in the current imaging modalities.
Read the full report: http://www.reportlinker.com/p02988993-summary/view-report.html
About Reportlinker
ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - instantly, in one place.
http://www.reportlinker.com
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
Share this article